[Results of a multicenter trial of serenoa repens extract (permixon) in patients with chronic abacterial prostatitis].

Abstract

Chronic prostatitis (CP) morbidity now makes up 8 to 35% in males aged 20-40 years (N.A. Lopatkin et al., 1998; O.L. Tiktinsky, 1999). In general population CP incidence rate is 5 to 8% (J.C. Nickel, 1999). Phytotherapy is now widely practiced in CP. A multicenter trial conducted by the authors demonstrates high efficacy ofpermixon in the treatment of chronic prostatitis/chronic pelvic pain syndrome. The results of 6-month follow-up are presented.

• Authors: N A Lopatkin, O I Apolikhin, A V Sivkov, Iu G Aliaev, B K Komiakov, V N Zhuravlev, V N Oshchepkov, A Z Vinarov, I V Bazhenov, A A Medvedev, L G Spivak, A G Eliseenko
• Journal: Urologiia (Moscow, Russia : 1999) (Urologiia) 2007 Sep-Oct Issue 5 Pg. 3-7 ISSN: 1728-2985 [Print] Russia (Federation)
• PMID: 18257155 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Androgen Antagonists
• Plant Extracts
• saw palmetto extract

Topics

• Adolescent
• Adult
• Androgen Antagonists (adverse effects, therapeutic use)
• Chronic Disease
• Humans
• Male
• Middle Aged
• Phytotherapy
• Plant Extracts (adverse effects, therapeutic use)
• Prostatitis (drug therapy)
• Serenoa
• Treatment Outcome